| 2.06 0.03 (1.48%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.46 | 1-year : | 2.58 |
| Resists | First : | 2.11 | Second : | 2.21 |
| Pivot price | 2.04 |
|||
| Supports | First : | 1.96 | Second : | 1.63 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 2.05  |
| MA(100) : | 2.03 |
MA(250) : | 2.4 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 25.3 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 3.95 | Low : | 1.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SERA ] has closed below upper band by 37.7%. Bollinger Bands are 70% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.1 | 2.1 - 2.11 |
| Low: | 2.01 - 2.02 | 2.02 - 2.03 |
| Close: | 2.04 - 2.06 | 2.06 - 2.08 |
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Wed, 14 Oct 2026
Sera Prognostics Q3 2026 Earnings Date and Estimates - MarketBeat
Wed, 14 Oct 2026
Form 4 Sera Prognostics Inc: Tiffany Eul Davis Inglis (Chief Medical Officer) For: 12 October - Investing.com Nigeria
Tue, 13 Oct 2026
Sera Prognostics (NASDAQ:SERA) Insider Tiffany Eul Davis Inglis Sells 8,024 Shares of Company Stock - MarketBeat
Tue, 13 Oct 2026
An officer’s 8,024-share sale at Sera Prognostics (SERA) was required to cover taxes, not discretionary. - Stock Titan
Fri, 11 Sep 2026
Sera Prognostics (NASDAQ: SERA) insider to sell shares to cover taxes - Stock Titan
Wed, 19 Aug 2026
Sera Prognostics Names Scott Gleason as CFO - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.771e+007 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 222 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.654e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -33 % |
| Return on Assets (ttm) | 346.6 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 70000 % |
| Gross Profit (p.s.) | 72.16 |
| Sales Per Share | -42.49 |
| EBITDA (p.s.) | -99056.6 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.44 |
| Dividend | 0 |
| Forward Dividend | 229720 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|